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Pyruvate (CH3COCOO-), a key intermediate in the oxidative and anaerobic
metabolism of glucose, has a potent reactive oxygen species scavenging effect.
The protective effects of pyruvate against oxidative stress have been reported.
1,2
Pyruvate also ameliorates organ injury or dysfunction in animal models of
myocardial,
3 cerebral,
4 intestinal,
5 and hepatic
6 ischemia/reperfusion (I/R) injury.
However, the use of pyruvate as a therapeutic agent is limited by its aqueous
instability; thus, its ethyl ester form is used as a practical pyruvate precursor for
administration.
7 Ethyl pyruvate (EP) is a lipophilic ester derivative of pyruvate,
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Purpose: Ethyl pyruvate has anti-inflammatory properties and protects organs
from ischemia/reperfusion (I/R)-induced tissue injury. The aim of this study was
to determine whether ethyl pyruvate decreases the inflammatory response after
regional I/R injury and whether ethyl pyruvate protects against delayed regional
I/R injury in an in vivo rat heart model after a 24 hours reperfusion. Materials and
Methods: Rats were randomized to receive lactated Ringer’s solution or ethyl
pyruvate dissolved in Ringer’s solution, which was given by intraperitoneal
injection 1 hour prior to ischemia. Rats were subjected to 30 min of ischemia
followed by reperfusion of the left coronary artery territory. After a 2 hours
reperfusion, nuclear factor κ B, myocardial myeloperoxidase activity, and
inflammatory cytokine levels were determined. After the 24 hours reperfusion, the
hemodynamic function and myocardial infarct size were evaluated. Results: At 2
hours after I/R injury, ethyl pyruvate attenuated I/R-induced nuclear factor κ B
translocation and reduced myeloperoxidase activity in myocardium. The plasma
circulating levels of inflammatory cytokines decreased significantly in the ethyl
pyruvate-treated group. At 24 hours after I/R injury, ethyl pyruvate significantly
improved cardiac function and reduced infarct size after regional I/R injury.
Conclusion: Ethyl pyruvate has the ability to inhibit neutrophil activation,
inflammatory cytokine release, and nuclear factor κ B translocation. Ethyl pyruvate
is associated with a delayed myocardial protective effect after regional I/R injury
in an in vivo rat heart model.  
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which has a myocardial protective effect in an in vivo
model by various mechanisms.
8,9
EP is an effective anti-inflammatory agent in a variety of
in vitro and in vivo model systems.
10-12 In the present study,
we used a regional myocardial I/R injury model to com-
pare the effects of treatment with lactated Ringer’s solution
and EP dissolved in Ringer’s solution on several physiol-
ogical and biochemical variables. 
Myocardial I/R injury is a major disease entity faced in
many clinical situations such as coronary thrombolytic
therapy, percutaneous transluminal coronary angioplasty,
coronary artery bypass graft, and cardiac transplantation.
In this situation, choosing the appropriate fluids to reduce
myocardial I/R injury is critical. 
The objectives of the study were to determine whether
EP decreases inflammatory response in myocardium and
plasma at 2 hours after I/R injury and whether EP has
delayed myocardial protective effects after regional I/R
injury at 24 hours post-I/R injury. 
Animal preparation
Male Sprague-Dawley rats (Sam Tako Inc., Osan, Korea)
weighing between 220 and 250 g were used for this study.
All animals were maintained in accordance with the
Guidelines for the Care and Use of Laboratory Animals
published by the US National Institutes of Health in 1996.
Animal preparation and surgery were done according to
previous report.
13 Animals received general anesthesia with
an intramuscular injection of 80 mg/kg ketamine (keta-
mine HCl
®, Huons, Seoul, Korea) and 8 mg/kg zylazine
(Rompun
®, Bayer Korea, Seoul, Korea). Once the rat tail
moved, we judged the rat as awakening from the anesthe-
sia. We additionally injected 40 mg/kg ketamine and 4
mg/kg zylazine to maintain the level of anesthesia. The
trachea was intubated, and the rats were mechanically
ventilated (tidal volume, 8 mL/kg; respiratory rate, 80 bpm)
with ambient air using a volume-controlled rodent venti-
lator (Type 7025; Ugo Basile, Comerio, Italy). Arterial
blood pH and gases were maintained within normal phy-
siological limits (pH 7.35-7.45, PaCO2 35-40 mmHg, PaO2
70-100 mmHg).
A paramedian sternotomy was performed, and the
pericardium was opened to expose the heart. For the I/R
experiments, a 4-0 black silk, nonabsorbable suture
(Mersilk; Ethicon Inc., Somerville, NJ, USA) was passed
around the left coronary artery (LCA) territory to induce
regional myocardial ischemia. Coronary artery occlusion
was achieved by tightening the snare through a small vinyl
chloride tube and clamping it with a mosquito hemostat.
Reperfusion was achieved by releasing the clamp. Myo-
cardial ischemia was verified by the appearance of regio-
nal epicardial cyanosis over the myocardial surface and
arrhythmia. After 30 min of ischemia, the myocardium
was reperfused by loosening the snare, which was main-
tained for 2 or 24 hours of reperfusion. Successful reper-
fusion was confirmed by the disappearance of epicardial
cyanosis and production of epicardial hyperemia and
arrhythmia after releasing the snare. The body temperature
was monitored with a rectal thermometer (Sirecust 1260;
Siemens Medical Electronics, MA, USA) and maintained
at 36-38˚C with an electrical heating pad. 
Experimental protocols
Each drug was administered intraperitoneally 1 hour
before the ischemic insult. We grasped the abdominal wall
with two fingers to protect the bowel organs from the drug
injection. We injected the drugs into the intraperitoneal
space with a 23 G needle and syringe. All animals under-
went a 30 min LCA occlusion followed by 2 or 24 hours
of reperfusion. The animals were randomly allocated into
two sets of experiments, with each set consisting of four
groups. The randomization was allocated by one author
with a numbered container. The sample size calculation is
based on our preliminary study. The appropriate sample
size was 7 by using PASS 2008 (Statistical & Power
Analysis Software; NCSS, Utah, USA). 
The first set of experiment
In the first set of experiments, 48 rats were divided into four
groups as follows. 1) Sham + 4 mL lactated Ringer’s solu-
tion (LR) group, sham-operated rats in which the LCA was
not tightened (n = 12); 2) sham + EP50 group, sham-operat-
ed rats in which 50 mg/kg EP dissolved in 4 mL Ringer’s
solution was administered intraperitoneally 1 hour before
the sham operation (n = 12); 3) I/R + LR group, rats in
which 4 mL LR was administered intraperitoneally 1 hour
before ischemic insult (n = 12); and 4) I/R + EP50 group,
rats in which 50 mg/kg EP dissolved in 4 mL Ringer’s solu-
tion was administered intraperitoneally 1 hour before ische-
mic insult (n = 12). Vehicle (LR 4 mL) or EP (50 mg/kg)
dissolved in 4 mL Ringer’s solution was administered by
intraperitoneal injection 1 hour before ischemia. The ani-
mals were exposed to 30 min of ischemia followed by 2
hours of reperfusion, and tissue samples (n = 6) were used
to detect NF-κ B translocation and myeloperoxidase (MPO)
activity. Blood samples (1 mL in each group, n = 6) were
collected at baseline and after 2 hours reperfusion in tubes
containing heparin to measure the tumor necrosis factor
(TNF)-α and interleukin (IL)-β‚ concentrations. The entire
sample was immediately centrifuged. Plasma was collect-
ed and frozen at -70˚C until analyzed.
MATERIALS AND METHODSThe second set of experiment
In the second set of experiments, animals were divided
into four groups as follows. 1) Sham + 4 mL lactated
Ringer’s solution (LR) group, sham-operated rats in which
the LCA was not tightened (n = 15); 2) I/R + LR group,
rats in which 4 mL LR was administered intraperitoneally
1 hour before ischemic insult (n = 15); 3) I/R + EP25
group dissolved in 4 mL Ringer’s solution, rats in which
25 mg/kg EP was administrated intraperitoneally 1 hour
before ischemic insult (n = 15); and 4) I/R + EP50 group,
rats in which 50 mg/kg EP dissolved in 4 mL Ringer’s
solution was administered intraperitoneally 1 hour before
ischemia insult (n = 15). The animals were exposed to 30
min of ischemia followed by a 24 hours reperfusion, and
infarct size and heart function was estimated. 
Preparation of nuclear and cyotplasmic proteins
The isolation of nuclear and cytoplasmic protein was done
according to previous report.
14 The heart sample area at
risks (AARs) were suspended in a buffer [10 mM Tris (pH
7.5), 1.5 mM MgCl2, 10 mM KCl, and 0.1% Triton X-100],
and lysed by homogenisation. The lysed sample was
isolated by microcentrifugation at 7,500 rpm for 5 min.
The supernatant, which contained cytoplasmic protein,
was collected and stored at -80˚C prior to Western blot
analysis. Nuclear proteins were extracted at 4˚C by resus-
pending the nuclear pellets in a buffer [20 mM Tris (pH
7.5), 20% glycerol, 1.5 mM MgCl2, 420 mM NaCl, 0.2
mM ethylenediaminetetraacetic acid (EDTA), and 0.1%
Triton X-100]. The nuclear pellets were left at 4˚C with
occasional vortex during 1 hour incubation. The pellets
were centrifuged at 13,000 rpm for 15 min, the supernatant
specimen that contained nuclear protein was collected. The
protein concentrations of the samples were equal in all
experiments.
Western blotting
Proteins were separated by SDS-PAGE, transferred to a
nitrocellulose membrane, and incubated with monoclonal
antibodies to nuclear factor (NF)-κ B p65 (Santa Cruz
Biotechnology, Inc., Santa Cruz, CA, USA) at 4˚C over-
night. Proteins were detected with horseradish peroxidase
(HRP)-conjugated secondary antibody (Santa Cruz Bio-
technology, Inc., Santa Cruz, CA, USA) [1 : 5,000 in Tris-
buffered saline and Tween 20 (TBS-T) containing 5%
skimmed milk powder for 1 hour at room temperature] and
were visualised by enhanced chemiluminescence.
Plasma cytokine measurement
ELISA kits (R&D Systems, Minneapolis, MN, USA) were
used for detection of TNF-α and IL-1β according to the
manufacturer’s instructions as earlier described.
14 The
plasma samples reacted with the assay reagents in the
TNF-α and IL-1β kits, respectively, and analyzed spec-
trophotometrically (Infinite
® F200; Tecan Group, Manne-
dorf, Switzerland) at an absorbance of 450 nm.
Evaluation of MPO activity
MPO activity, a marker for neutrophil accumulation, was
evaluated according to the method of Bradley, et al. Myo-
cardial tissue (ca. 500 mg) was excised from the AAR
after 2 hours reperfusion and homogenized in 50 mM/L
potassium phosphate buffer at pH 6.0. The samples were
centrifuged for 30 min at 20,000 g and 4˚C before extrac-
tion. The resulting pellets were used to measure MPO
activity after suspension in 50 mM/L potassium phosphate
buffer containing 0.5% hexadecyltrimethyl ammonium
bromide. The pellets were centrifuged at 20,000 g for 15
min; a 0.2 mL supernatant specimen was added to 0.8 mL
of 50 mM/L potassium phosphate buffer (pH 6.0) con-
taining 0.167 mg/mL 3,3’-dimethoxybenzidine dihydro-
chloride and 0.0005% hydrogen peroxide. Absorbance
was measured spectrophotometrically at 460 nm using a
spectrophotometer (Lambda EZ 210; PerkinElmer, Walt-
ham, MA, USA) for 2 min. One unit of MPO was defined
as the activity that degraded 1 µM/min peroxide at 25˚C.
Measurement of hemodynamic variables and 
myocardial contractility
After the 24 hours reperfusion, rats were anesthetised with
30 mg/kg ketamine and 3 mg/kg xylazine. The right
common carotid artery was cannulated with a 2-Fr Millar
catheter (Model SPR-407; Millar Instruments, Houston,
TX, USA) and the catheter was advanced into the left
ventricle (LV) to measure heart rate (HR), left ventricular
end diastolic pressure (LVEDP), and maximum rate of LV
pressure increase (+dP/dtmax) and decrease (-dP/dtmax). 
Determination of the area at risk and infarct size 
After the cardiac function analysis, the LCA was occluded
again and 2 mL of 1% Evans blue dye was injected into
the pulmonary artery to facilitate AAR determination. The
Evans blue dye stained the perfused myocardium, whereas
the occluded vascular bed remained unstained. The atria,
right ventricles, and major vessels were removed from the
heart, and the AAR was separated from the non-ischemic
area. The AAR was cut into small pieces and incubated in
2% 2,3,5-triphenyltetrazolium chloride (TTC) at 37˚C for
20 min. The TTC stained the non-infarcted myocardium a
deep red color, and the infarcted area (IA) remained pale
yellow. The sections were fixed in 2% formalin solution
for 24 hours. The LV, AAR, and IA weights were cal-
culated. The AAR was expressed as a percentage of the
LV weight, and the IA as a percentage of the AAR weight.
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All values are expressed as the mean ± SD. All statistical
analyses were performed using statistics software (ver.
10.0 for Windows; SPSS Inc., Chicago, IL, USA). Differ-
ences in the relationship amongst groups were evaluated
by the Friedman one-way ANOVA and post hoc Duncan’s
multiple comparison test. Statistical significance was
determined as p< 0.05. 
EP modulates inflammatory signalling pathways and 
modifies NF-κ κ B activation
The changes in the cytosolic and nuclear extractions are
shown in Fig. 1. NF-κ B expression in the cytosolic frac-
tion was attenuated significantly in the I/R + LR group
compared to the sham + LR group. In contrast, expression
in the nuclear fraction was enhanced in the I/R + LR
group; however, this change was inhibited by EP pre-
treatment, which suggests that I/R-induced NF-κ B translo-
cation into the nucleus was inhibited by EP. 
EP decreases production of inflammatory mediators 
and MPO activity 
I/R induced a significant increase in the plasma levels of
inflammatory cytokines after the 2 hours reperfusion (Fig.
2). However, in the I/R + EP50 group, the elevation in
plasma TNF-α concentration was inhibited significantly
compared to that in the I/R + LR group (75 ± 36.7 vs. 152
± 48.9 pg/mL plasma, p= 0.010). The IL-1βlevel was also
reduced in the I/R + EP50 group compared to the I/R + LR
group (105 ± 56 vs. 216 ± 85 pg/mL plasma, p = 0.040).
The TNF-α and IL-1β levels were not significantly
different between the Sham + LR and Sham + EP50. MPO
activity in the ischemic area of the myocardium was
reduced significantly in the I/R + EP50 group compared to
the I/R + LR group (64 ± 7.4 vs. 86 ± 12.1 U/g tissue, p =
0.030) after regional I/R injury (Fig. 3).
Ethyl Pyruvate in Myocardial Protection
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Fig. 1. Effect of EP on I/R-induced translocation of NF-κ B. Representative illust-
ration of NF-NF-κ Bexpression in the cytosolic and nuclear fractions of rat ische-
micmyocardium by Western blotting. Sham + LR, sham-operated rats in which
no tightening of the left coronary artery was performed; sham + EP50, sham-
operated rats in which 50 mg/kg EP was administered intraperitoneally 1 hour
before ischemic insult; I/R + LR, rats in which 4 mL LR was administered intra-
peritoneally 1 hour before ischemic insult; I/R + EP50, rats in which 50 mg/kg EP
was administered intraperitoneally 1 hour before ischemic insult. NF-NF-κ B,
nucl-ear factor-NF-κ B; NE, nuclear extraction; CE, cytosolic extraction; I/R,
ischemia/reperfusion; EP, ethyl pyruvate; LR, lactated Ringer’s solution. *p <
0.05 vs. sham + LR. 
�p< 0.05 vs. sham + EP50. 
�p< 0.05 vs. I/R + LR.
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Fig. 2. Cardiac production of pro-inflammatory cytokines. Plasma levels of TNF-
αand IL-1β‚ at 2 hours post-reperfusion in each group. Values are the mean ±
SD (n = 6 in each group). Sham + LR, sham-operated rats in which no tightening
of the left coronary artery was performed; sham + EP50, sham-operated rats in
which 50 mg/kg EP was administered intraperitoneally 1 hour before ischemic
insult; I/R + LR, rats in which 4 mL LR was administered intraperitoneally 1 hour
before ischemic insult; I/R + EP50, rats in which 50 mg/kg EP was administered
intraperitoneally 1 hour before ischemic insult. TNF-α, tumor necrosis factor-α;
IL-1β, interleukin-1β; I/R, ischemia/reperfusion; EP, ethyl pyruvate; LR, lactated
Ringer’s solution. *p< 0.05 vs. sham + LR. 
�p< 0.05 vs. sham + EP50. 
�p< 0.05 vs.
I/R + LR.
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Fig. 3.MPO activity was expressed as U/g area at risk (AAR) obtained from the
sham + LR, sham + EP50, I/R + LR, and I/R + EP50 groups. Values are the mean
±SD (n = 6 in each group). Sham + LR, sham-operated rats in which no tighten-
ing of the left coronary artery was performed; sham + EP50, sham-operated
rats in which 50 mg/kg EP was administered intraperitoneally 1 hour before
ischemic insult; I/R + LR, rats in which 4 mL LR was administered intraperi-
toneally 1 hour before ischemic insult; I/R + EP50, rats in which 50 mg/kg EP
was administered intraperitoneally 1 hour before ischemic insult. MPO activity,
myeloperoxidase activity; I/R, ischemia/reperfusion; EP, ethyl pyruvate; LR,
lactated Ringer’s solution. *p< 0.05 vs. sham + LR. 
�p< 0.05 vs. sham + EP50. 
�p
< 0.05 vs. I/R + LR.
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Sham                     I/REP improves cardiac function after I/R injury
Hemodynamic measurements recorded at 24 hours after
reperfusion revealed substantial LV dysfunction as demons-
trated by an increased LVEDP (11.9 ± 2.2 vs. 5.7 ± 1.3
mmHg, p< 0.001) and decreased contractility. The +dP/dtmax
shows the decreased contractility in the I/R + LR group
compared to the sham + LR group (+3,202 ± 260 vs. +3,958
± 189 mmHg/sec, p < 0.001). The -dP/dtmax shows the dec-
reased contractivity in the I/R + LR group compared to the
sham + LR group (- 2,605 ± 247 vs. - 3,236 ± 321 mmHg/
sec, p < 0.001) (Table 1). The +dP/dtmax shows an inhibited
decrease of contractility in the I/R + EP50 compared to the
I/R + LR group (+3,510 ± 247 vs. +3,202 ± 260 mmHg/
sec, p = 0.002). Also, the -dP/dtmax shows an inhibited
decrease of contractility in the I/R + EP50 compared to the
I/R + LR group (- 2,979 ± 202 vs. - 2,605 ± 247 mmHg/sec,
p < 0.001). Moreover, the elevated LVEDP was significan-
tly attenuated in the I/R + EP50 group (8.2 ± 2.0 vs. 11.9 ±
2.2 mmHg, p < 0.001). Consequently, EP significantly
recovered heart function after myocardial I/R injury (Table 1).
EP reduces infarct size
No significant differences were found in the AAR/LV
induced by LCA occlusion among the groups. The IA/
AAR was 51 ± 4% in the I/R + LR group and 44 ± 3% in
the I/R + EP25 group (p = 0.040 vs. I/R + LR group). How-
ever, in the I/R + EP50 group, IA/AAR was reduced signi-
ficantly to 36 ± 2% (p= 0.014 vs. I/R + LR group) (Fig. 4). 
We found that myocardial I/R injury activated the NF-κ B-
induced inflammatory response, whereas EP pre-treatment
resulted in an attenuation of NF-κ B translocation, inflam-
matory mediator expression, and myocardial MPO activity.
The protective effects of EP may be attributable, in part, to
suppression of the inflammatory response via down-
regulation of NF-κ B-induced inflammation by I/R injury
after reperfusion. Other studies have reported that inflam-
matory cytokines and MPO activity are elevated between
30 and 60 min after reperfusion.
15-17 NF-κ B levels increas-
ed biphasically in post-ischemic tissue with peak levels at
15 min and again at 3 hours after reperfusion
18; thus, we
checked NF-κ B translocation and MPO activity in myo-
cardial tissue and the serum inflammatory cytokine levels
at 2 hours after reperfusion. 
NF-κ B increases the expression of the genes for many
cytokines, enzymes, and adhesion molecules in an inflam-
matory situation. The activation of NF-κ B therefore leads
to a coordinated increase in the expression of many genes
whose products mediate inflammatory responses.
19 NF-κ B
has been identified as a transcription factor and plays an
important role in the onset of inflammatory responses
In-Seok Jang, et al.
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DISCUSSION
Table 1.Hemodynamic Data under Ischemia/Reperfusion Conditions
LVSP LVEDP +dP/dtmax -dP/dtmax
(mmHg) (mmHg) (mmHg/sec) (mmHg/sec)
Sham + LR (n = 15) 111 ± 7 5.7 ± 1.3 3,958 ± 189 - 3,236 ± 321
I/R + LR (n = 15) 92 ± 8* 11.9 ± 2.2* 3,202 ± 260* - 2,605 ± 247*
I/R + EP25 (n = 15) 95 ± 8 10.1 ± 1.5*
,� 3,248 ± 139* - 2,683 ± 141*
I/R + EP50 (n = 15) 100 ± 7 8.2 ± 2.0*
,�,� 3,510 ± 247*
,�,� - 2,979 ± 202
�,�
Values are the mean ± SD. Sham + LR, sham-operated rats in which no tightening of the left coronary artery was performed; I/R + LR, rats in 
which 4 mL LR was administered intraperitoneally 1 hour before ischemic insult; I/R + EP25, rats in which 25 mg/kg EP was administrated
intraperitoneally 1 hour before ischemic insult; I/R + EP50, rats in which 50 mg/kg EP was administered intraperitoneally 1 hour before
ischemic insult.
LVSP, left ventricular systolic pressure; LVEDP, left ventricular end diastolic pressure; I/R, ischemia/reperfusion; EP, ethyl pyruvate; LR,
lactated Ringer’s solution.
*p< 0.05 vs. sham + LR.
�p< 0.05 vs. I/R + LR.
�p< 0.05 vs. I/R + EP25.
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Fig. 4.Comparison of myocardial infarct size in the I/R + LR, I/R + EP25, and I/R +
EP50 groups. Values are means ± SD (n = 15 in each group). I/R + LR, rats in
which 4 mL LR was administered intraperitoneally 1 hour before ischemic insult;
I/R + EP25, rats in which 25 mg/kg EP was administrated intraperitoneally 1 hour
before ischemic insult; I/R + EP50, rats in which 50 mg/kg EP was administered
intraperitoneally 1 hour before ischemic insult. I/R, ischemia/reperfusion; LR,
lactated Ringer’s solution; EP, ethyl pyruvate; AAR, area at risk; LV, left ventricle;
IA, infracted area.  *p< 0.05 compared to the I/R + LR group.stimulated by pro-inflammatory cytokines such as TNF-α,
IL-1, IL-6, and IL-8.
10-12 Because EP inhibits NF-κ B
activation in a variety of in vivo and in vitro systems, the
myocardial protective effect of EP may be related to NF-κ
B inactivation by anti-inflammatory agents.
11,12,20 EP pre-
treatment resulted in the attenuation of NF-κ B translo-
cation and the levels of TNF-α and IL-1β. The protective
effects of EP may be partially attributable to suppression of
the inflammatory response via down-regulation of NF-κ B.
EP reduced myocardial I/R injury by inactivating NF-κ
B. Our results suggest that EP exerts myocardial protection
by inhibiting the inflammatory process and that it may be
related to down-regulation of NF-κ B translocation. A
previous study showed that I/R injury is associated with
activation of NF-κ B in various organs such as the liver,
21
kidney,
22 and brain.
11 The present results show that myo-
cardial I/R injury-induced NF-κ B activation are consistent
with these observations.
Myocardial I/R injury initiates an acute inflammatory
response.
23 Accumulation of polymorphonuclear leuko-
cytes (PMNs) is major evidence of acute inflammation,
and the infiltration of PMNs initiates myocardial damage
by releasing oxygen free radicals, proteases, and leuko-
trienes.
23,24 The MPO activity assay for PMN activation
should be checked because MPO is mainly released from
PMNs.
24,25 In the present study, MPO activity was inhibited
by EP treatment; thus, EP may exert a protective effect by
inhibiting PMN activity.
We also showed that EP improved cardiac function and
reduced myocardial infarct size after regional I/R injury in
an in vivo rat heart model after a 24 hours reperfusion.
Myocardial infarction reaches a peak at 24 hours, whereas
myocardial ischemia progressively develops during the
late reperfusion period.
26,27 Myocardial infarction was
progressively extended between 6 and 24 hours, so we
obtained the hemodynamic parameters and checked the
infarction size 24 hours after reperfusion to identify the
myocardial protective effect of EP. Other studies have
reported reperfusion injury and infarction less than 60 min
after ischemia, but our results showed a delayed phase in
the myocardial reperfusion injury 24 hours after ischemia.
So, EP can be used to protect myocardium in a clinical
situation such as coronary artery bypass graft operation,
heart transplantation, and many cardiac reperfusion
procedures. EP dissolved in Ringer’s solution may be
helpful fluid therapy for these situations. 
Our study has some limitations. First, a time gap existed
between the anti-inflammatory markers and hemodynamic
function/infarct size, so we did not clearly correlate the
relationship and assumed that the myocardial protection
was caused by the anti-inflammatory effect of EP. Second,
because of technical difficulty, we could not check the
hemodynamic parameters during the baseline or the
ischemic period, so we only checked the hemodynamic
parameters 24 hours after reperfusion. Third, we used EP
at 25 and 50 mg/kg. In a future study, increased EP con-
centrations should be evaluated for further myocardial pro-
tective effects.
In conclusion, EP inhibited MPO activity, inflammatory
cytokine release, and NF-κ B translocation during the anti-
inflammatory response. EP was associated with a delayed
myocardial protective effect after regional I/R injury in an
in vivo rat heart model. This protective effect may have been
attributable at least in part to suppression of the inflam-
matory response.
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